Solid Biosciences Q2 net loss widens on higher R&D costs

Solid Biosciences

06/08/2026 21:23

Overview
US gene therapy developer reported Q2 net loss widened yr/yr on higher R&D and G&A costs
Company ended Q2 with $377.7 mln in cash, expects runway into mid-2028
Solid advanced Duchenne and Friedreich’s ataxia trials, with FDA meeting on SGT-003 planned for late 2026

Outlook
Solid expects to meet with FDA in late Q4 2026 on SGT-003 accelerated approval pathway
Company expects initial SGT-212 Phase 1b data in Q1 2027, subject to enrollment
Solid anticipates existing cash will fund operations into mid-2028

Result Drivers
R&D SPENDING - Higher Q2 research and development expenses mainly due to increased costs for SGT-003 manufacturing and clinical activities, as well as SGT-212 clinical and research costs
G&A EXPENSES - General and administrative expenses rose mainly due to higher personnel, business development, equipment, and consulting costs

Company press release: ID:nGNXb3MtPr

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$54.8 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 83.3% above its August 5 closing price of $8.73

Reuters Recommended Reads
Aug 5 - Sarepta Q2 results beat expectations despite lower sales stemming from Elevidys relabel, unmet Roche milestone
Aug 6 - Intellia Therapeutics Q2 collaboration revenue falls, net loss widens
Aug 6 - Regenxbio Q2 revenue surges on AbbVie milestone payment

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)